Shift Health has led a study showing that we are systematically underestimating the global socioeconomic burden of Alzheimer’s disease. The hidden costs have important implications for policymakers.
A Shift Health study shows that available treatments for people living with haemophilia A impact psychological wellbeing, employment opportunities and adherence to treatment regimens, helping to inform decision‐making around the value innovative treatments.
Driven by emerging clinical evidence and increasingly favourable regulatory conditions, companies are racing to develop cannabis-based pharmaceuticals for diverse indications. In this paper, we explore three trends that we believe will critically shape the cannabis industry over the coming years.
Shift Health partnered with the Global HIV Vaccine Enterprise to pilot a two-day Boot Camp aimed at educating vaccine development partners across sectors—academia, government, funders, NGOs, industry—on strategies, tools and best practices enabling product development.
The Pox-Protein Public-Private Partnership (P5)—has enlisted Shift Health to help advance priorities and achieve several partnership goals over the course of a multi-year product development plan
Public-private partnerships (P3s) have become an increasingly pivotal—almost doctrinal—driver of R&D across the health sciences. But for all the advantages that have made P3s increasingly inevitable, these partnerships have not become less complex.
Shift Health co-hosted a Product Development Boot Camp with the Global HIV Vaccine Enterprise. Ryan Wiley, PhD, President at Shift Health, delivered an overview of product development partnerships.
Shift Health co-hosted a Product Development Boot Camp with the Global HIV Vaccine Enterprise, affording participants an opportunity to discuss best practices, learn from other experts and create an enduring toolkit that will serve the HIV vaccine field and beyond.
Clinical experience and patients’ needs drive science, ensuring the flow of knowledge and innovation from ‘bench to bedside to population to bench’. This paper discusses the conditions for success for Saudi Arabia to capitalize on translational research.